You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海普瑞(002399.SZ)隨A股同業彈逾4% 惟在港上市H股海普瑞(09989.HK)持續「潛水」
阿思達克 07-13 11:00
國務院金融穩定發展委員會開會促請打擊資本市場違法行為,銀監會周未發文嚴禁金融業違規資金流入股市及樓市,以及銀行和保險公司參與場外配資。滬指及深成繼上周五分別由兩年半高位及逾五年半回吐近1.9%及0.6%結束八連漲後,前者今天低開後反覆回升0.8%報3,410,後者續升2%報13,952。板塊方面,生物疫苗板塊急漲逾5%居榜首。

於深圳上市的海普瑞A股(002399.SZ)也隨同業彈4.1%報27元人民幣。不過,於本港上市海普瑞藥業(09989.HK)上市第四天,股價持續「潛水」,繼首掛日高見18.68元無以為繼,今天更一度跌至17元才喘定,曾反彈至17.44元,現造17.24元,續跌1.4%,成交474萬股。

海普瑞是內地領先製藥公司,在製藥領域、創新生物科技領域及CDMO領域擁有全球業務。根據弗若斯特沙利文資料,按2019年全球銷售額計,海普瑞是內地最大及全球第三大依諾肝素鈉注射液生產商及銷售商,佔據6.5%全球市場份額。海普瑞今次來港發發售逾2.2億股H股,並已引入OrbiMed Funds、AVICT、歐萬達基金、3W及Anlan Funds為基石投資者,合共認購4,630.75萬股H股(設有6個月禁售期);其中10%公開發售獲逾68倍超購,已啟動回撥機制佔比增至40%,認購一手中籤率40%;股份以招股範圍(18.4-20.6元)下限定價,料集資淨額約38.06億元,主要用作還債、於歐洲及其他市場發展營銷網絡和基建、提升研發生產能力及用於創新藥投資等。上市聯席保薦人大摩及高盛。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account